|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
ELV03312177X |
| 003 |
DE-627 |
| 005 |
20230625193009.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
180603s2013 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/S0378-3782(13)70127-0
|2 doi
|
| 028 |
5 |
2 |
|a GBVA2013012000013.pica
|
| 035 |
|
|
|a (DE-627)ELV03312177X
|
| 035 |
|
|
|a (ELSEVIER)S0378-3782(13)70127-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
4 |
|a 610
|q DE-600
|
| 082 |
0 |
4 |
|a 618.3/005
|q OCLC
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 084 |
|
|
|a 44.45
|2 bkl
|
| 100 |
1 |
|
|a Antonucci, Roberto
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Is sucrose useful in neonatal medicine?
|
| 264 |
|
1 |
|c 2013transfer abstract
|
| 300 |
|
|
|a 3
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
| 338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
| 520 |
|
|
|a The use of oral sucrose for procedural pain relief has been extensively studied in newborn infants. In general, sucrose or other sweet solutions have been shown to significantly reduce pain responses to common painful procedures (e.g. heel lance or venipuncture) in newborn and young infants. The analgesic effect of sucrose seems to peak at about two minutes after administration by mouth and to last for several minutes. The mechanisms underlying sucrose-induced analgesia in human infants are not fully understood, but the endogenous opioid system seems to play a key role. The optimal dose of sucrose remains unclear, although doses from 0.012 g to 0.12 g (0.05–0.5 mL of 24% solution) have been reported to be effective. No clinically significant side effects have been observed with the use of single doses of sucrose. Currently, oral sucrose appears to be safe and effective for relieving procedural pain from single events in neonates, while more research is needed to clarify the effect of repeated sucrose administration on immediate and long-term outcomes, especially in extremely preterm, unstable, ventilated neonates. This paper provides an overview of existing evidence on sucrose-induced analgesia and its mechanisms, highlighting current knowledge gaps.
|
| 520 |
|
|
|a The use of oral sucrose for procedural pain relief has been extensively studied in newborn infants. In general, sucrose or other sweet solutions have been shown to significantly reduce pain responses to common painful procedures (e.g. heel lance or venipuncture) in newborn and young infants. The analgesic effect of sucrose seems to peak at about two minutes after administration by mouth and to last for several minutes. The mechanisms underlying sucrose-induced analgesia in human infants are not fully understood, but the endogenous opioid system seems to play a key role. The optimal dose of sucrose remains unclear, although doses from 0.012 g to 0.12 g (0.05–0.5 mL of 24% solution) have been reported to be effective. No clinically significant side effects have been observed with the use of single doses of sucrose. Currently, oral sucrose appears to be safe and effective for relieving procedural pain from single events in neonates, while more research is needed to clarify the effect of repeated sucrose administration on immediate and long-term outcomes, especially in extremely preterm, unstable, ventilated neonates. This paper provides an overview of existing evidence on sucrose-induced analgesia and its mechanisms, highlighting current knowledge gaps.
|
| 650 |
|
7 |
|a Analgesia
|2 Elsevier
|
| 650 |
|
7 |
|a Newborn
|2 Elsevier
|
| 650 |
|
7 |
|a Sucrose
|2 Elsevier
|
| 650 |
|
7 |
|a Procedural pain
|2 Elsevier
|
| 700 |
1 |
|
|a Antonucci, Luca
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|n Elsevier Science
|a Abdel-Aziz, Tarek Ezzat ELSEVIER
|t Study of serum leptin in well differentiated thyroid carcinoma: Correlation with patient and tumor characteristics
|d 2014
|g Amsterdam [u.a.]
|w (DE-627)ELV022803173
|
| 773 |
1 |
8 |
|g volume:89
|g year:2013
|g pages:123-125
|g extent:3
|
| 856 |
4 |
0 |
|u https://doi.org/10.1016/S0378-3782(13)70127-0
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_U
|
| 912 |
|
|
|a GBV_ELV
|
| 912 |
|
|
|a SYSFLAG_U
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_350
|
| 936 |
b |
k |
|a 44.45
|j Immunologie
|q VZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 89
|j 2013
|h 123-125
|g 3
|y 89.2013, S123-, (3 S.)
|
| 953 |
|
|
|2 045F
|a 610
|